Do Urate Targets Influence CV Risk?
Researchers examine whether achieving treat-to-target serum urate levels with urate-lowering treatment affects long-term cardiovascular outcomes in patients with gout.
-
By
-
Kathryn Wighton
-
January 30, 2026
-
-
1
Fewer than one-third of gout patients achieved serum urate targets within 12 months, impacting cardiovascular risk.
-
2
Achieving urate levels below 6 mg/dL was linked to a 9% relative risk reduction for major adverse cardiovascular events.
-
3
Patients with high cardiovascular risk saw a 23% relative risk reduction when urate levels were lowered below 5 mg/dL.
-
4
The study involved 109,504 adults, with a mean follow-up of 3.5 years, revealing a 14% incidence of major adverse cardiovascular events.
-
5
Treat-to-target therapy not only improved cardiovascular outcomes but also resulted in fewer gout flares among patients.
